UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Nature communications, 2021-02, Vol.12 (1), p.1047-1047, Article 1047

2021

Link zum Volltext

Verfügbarkeit prüfen

Dampening enthusiasm for circulating microRNA in breast cancer

PloS one, 2013-03, Vol.8 (3), p.e57841-e57841

2013

Link zum Volltext

Verfügbarkeit prüfen

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

Nature communications, 2018-07, Vol.9 (1), p.2724-13, Article 2724

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of explant responses to STING ligands: personalized immunosurgical therapy for head and neck squamous cell carcinoma

Cancer research (Chicago, Ill.), 2018-11, Vol.78 (21), p.6308-6319

2018

Link zum Volltext

Verfügbarkeit prüfen

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

Journal for immunotherapy of cancer, 2019-07, Vol.7 (1), p.165-11, Article 165

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Clinical cancer research, 2020-10, Vol.26 (20), p.5358-5367

2020

Link zum Volltext

Verfügbarkeit prüfen

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Journal for immunotherapy of cancer, 2019-07, Vol.7 (1), p.184-184, Article 184

2019

Link zum Volltext

Verfügbarkeit prüfen

Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors

Cancer, 2021-12, Vol.127 (24), p.4565-4573

2021

Link zum Volltext

Verfügbarkeit prüfen

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

Carcinogenesis (New York), 2010-04, Vol.31 (4), p.577-586

2010

Link zum Volltext

Verfügbarkeit prüfen

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Clinical cancer research, 2020-03, Vol.26 (5), p.1025-1033

2020

Link zum Volltext

Verfügbarkeit prüfen

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

Journal for immunotherapy of cancer, 2016-11, Vol.4 (1), p.70-70, Article 70

2016

Link zum Volltext

Verfügbarkeit prüfen

STING expression and response to treatment with STING ligands in premalignant and malignant disease

PloS one, 2017-11, Vol.12 (11), p.e0187532-e0187532

2017

Link zum Volltext

Verfügbarkeit prüfen

Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies

Clinical cancer research, 2023-06, Vol.29 (12), p.2173-2175

2023

Link zum Volltext

Verfügbarkeit prüfen

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

Journal of translational medicine, 2023-07, Vol.21 (1), p.508-508, Article 508

2023

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002568

2021

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002485

2021

Link zum Volltext

Verfügbarkeit prüfen

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease

PloS one, 2018-02, Vol.13 (2), p.e0192988-e0192988

2018

Link zum Volltext

Verfügbarkeit prüfen

Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes

Frontiers in oral health, 2022-07, Vol.3

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

International journal of radiation oncology, biology, physics, 2023-03, Vol.115 (4), p.847-860

2023

Link zum Volltext

Verfügbarkeit prüfen

The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis

Genes chromosomes & cancer, 2012-05, Vol.51 (5), p.473-479

2012

Link zum Volltext

Verfügbarkeit prüfen

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment

Oral oncology, 2016-01, Vol.52, p.1-10

2016

Link zum Volltext

Verfügbarkeit prüfen

Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens

Lung cancer (Amsterdam, Netherlands), 2014-07, Vol.85 (1), p.31-39

2014

Link zum Volltext

Verfügbarkeit prüfen

Genetic Abnormalities of the EGFR Pathway in African American Patients With Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-11, Vol.27 (33), p.5620-5626

2009

Link zum Volltext

Verfügbarkeit prüfen

Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival

Oral oncology, 2020-10, Vol.109, p.104770, Article 104770

2020

Link zum Volltext

Verfügbarkeit prüfen

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Journal for immunotherapy of cancer, 2021-04, Vol.9 (4), p.e002371

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Englisch
(109)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Dampening enthusiasm for circulating microRNA in breast cancer

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

Evaluation of explant responses to STING ligands: personalized immunosurgical therapy for head and neck squamous cell carcinoma

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

STING expression and response to treatment with STING ligands in premalignant and malignant disease

Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease

Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes

Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment

Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens

Genetic Abnormalities of the EGFR Pathway in African American Patients With Non–Small-Cell Lung Cancer

Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Suchergebnisse filtern